Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion.

Brain tumor pathology - 1 Apr 2018

Yamamichi Akane, Ohka Fumiharu, Aoki Kosuke, Suzuki Hiromichi, Kato Akira, Hirano Masaki, Motomura Kazuya, Tanahashi Kuniaki, Chalise Lushun, Maeda Sachi, Wakabayashi Toshihiko, Kato Yukinari, Natsume Atsushi

Abstract excerpt

The IDH-mutant and 1p/19q co-deletion (1p19q codel) provides significant diagnostic and prognostic value in lower-grade gliomas. As ATRX mutation and 1p19q codel are mutually exclusive, ATRX immunohistochemistry (IHC) may substitute for 1p19q codel, but this has not been comprehensively examined. In the current study, we performed ATRX-IHC in 78 gliomas whose ATRX statuses were comprehensively determined by whole...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exome Sequencing

Share to Gene Deletion

Share to Gene Expression

Share to Glioma

Share to Immunohistochemistry

Share to X-linked Nuclear Protein

Source

Identifiers

PMID: 29550880
DOI: 10.1007/s10014-018-0312-5

Genes

ATRX

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion.PMID 29550880Read ↗

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.Semantic proximity Read ↗

HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.Semantic proximity Read ↗

Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.Semantic proximity Read ↗

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.Semantic proximity Read ↗

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.Semantic proximity Read ↗

Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas.Semantic proximity Read ↗

Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.Semantic proximity Read ↗

1p/19q testing has no significance in the workup of glioblastomasSemantic proximity Read ↗

ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.Semantic proximity Read ↗

Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas.Semantic proximity Read ↗

Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens.Semantic proximity Read ↗

Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.